Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo

International Immunopharmacology

Volumn 7, Issue 13, 2007, Pages 1732-1740

  Zhang, Linghua ^a   Tian, Xingshan ^b   Zhou, Fengzhen ^b  

^a SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^b INSTITUTE OF ANIMAL SCIENCE   (China)

Author keywords

CpG ODN; Immune responses; Porcine reproductive and respiratory syndrome (PRRS) killed virus vaccine; The piglets

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL HUSBANDRY; ARTERIVIRUS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FECES ANALYSIS; HELPER CELL; IMMUNE RESPONSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE SECRETION; PERIPHERAL BLOOD MONONUCLEAR CELL; PIGLET; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; IMMUNITY, MUCOSAL; INTERFERON TYPE II; INTERLEUKIN-6; OLIGODEOXYRIBONUCLEOTIDES; PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS; SWINE; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 35848965051     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.09.012     Document Type: Article

References (54)

1. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10 (1992) 75-88
2. Staats H.F., Jackson R.J., Marinaro M., Takahashi I., Kiyono H., and McGhee J.R. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol 6 (1994) 572-583
3. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., and McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170 11 (2003) 5636-5643
4. BenMohamed L., Belkaid Y., Loing E., Brahimi K., Gras-Masse H., and Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 32 8 (2002) 2274-2281
5. Kaul D., and Ogra P.L. Mucosal responses to parenteral and mucosal vaccines. Dev Biol Stand 95 (1998) 141-146
6. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12 (1994) 387-400
7. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
8. Klinman D.M., Conover J., and Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 67 11 (1999) 5658-5663
9. Yi A.K., Chace J.H., Cowdery J.S., and Krieg A.M. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 156 2 (1996) 558-564
10. Halpern M.D., Kurlander R.J., and Pisetsky D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol 167 1 (1996) 72-78
11. Cowdery J.S., Chace J.H., Yi A.K., and Krieg A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 156 12 (1996) 4570-4575
12. Ballas Z.K., Rasmussen W.L., and Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157 (1996) 1840-1845
13. Yamamoto S., Yamamoto T., Nojima Y., Umemori K., Phalen S., McMurray D.N., et al. Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development. Jpn J Infect Dis 55 (2002) 37-44
14. Krieg A., and Davis H. Enhancing vaccine with immune stimulatory CpG DNA. Curr Opin Mol Ther 3 (2001) 15-24
15. Harandi A.M., and Holmgren J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr Opin Investig Drugs 5 (2004) 141-145
16. Zhang L.H., Tian X.S., Guo Y., and Zhou F.Z. The effect of transgenic expression of porcine interleukin-6 gene and CpG sequences on immune responses of the newborn piglets inoculated with pseudorabies attenuated vaccine. Res Vet Sci 80 (2006) 281-286
17. Zhang L.H., Tian X.S., Guo Y., and Zhou F.Z. Effects of CpG ODN on CD4+ and CD8+T subpopulations in the immune response to porcine reproductive and respiratory syndrome killed virus vaccine. Vaccine 24 11 (2006) 1874-1879
18. Van der Stede Y., Verdonck F., Vancaeneghem S., Cox E., and Goddeeris B.M. CpG-oligodinucleotides as an effective adjuvant in pigs for intramuscular immunizations. Vet Immunol Immunopathol 86 (2002) 31-41
19. Lewis P.J., van Drunen Little-van den Hurk S., and Babiuk L.A. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 73 (1999) 10214-10223
20. Masuda K., Sakaguchi M., Saito S., Deboer D.J., Fujiwara S., Kurata K., et al. In vivo and in vitro tests showing sensitization to Japanese cedar (Cryptomeria japonica) pollen allergen in atopic dogs. J Vet Med Sci 62 (2000) 995-1000
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
22. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. Modification to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89 (1986) 271-277
23. Riedl P., Buschle M., Reimann J., and Schirmbeck R. Binding immunostimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants. Eur J Immunol 32 6 (2002) 1709-1716
24. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T Helper 1 (Th1) immunity. J Exp Med 186 10 (1997) 1623-1631
25. Wai M.L., Marcel B.B., and Schutze-Redelmeier M.P. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20 (2002) 148-157
26. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., and Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A 95 (1998) 15553-15558
27. Davis H.L., Suparto I., Weeratna R., Jumintarto, Iskandriati D., Chamzah S., et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18 18 (2000) 1920-1924
28. Sun S., Zhang X., Tough D.F., and Sprent J. Type 1 interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188 12 (1998) 2335-2342
29. Threadgill D.S., McCormick L.L., McCool T.L., Greenspan N.S., and Schreiber J.R. Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. Vaccine 16 (1998) 76-82
30. Carpentier A.F., Chen L., Maltonti F., and Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59 (1999) 5429-5432
31. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., and van Drunen Little-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21 (2002) 127-137
32. Jakob T., Walker P.S., Krieg A.M., Udey M.C., and Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161 (1998) 3042-3049
33. McCluskie M.J., and Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161 (1998) 4463-4466
34. McCluskie M.J., and Davis H.L. CpG DNA as mucosal adjuvant. Vaccine 18 (2000) 231-237
35. Horner A.A., Ronaghy A., Cheng P.M., Nguyen M.D., Cho H.J., and Broidem D. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 190 (1998) 77-82
36. Moldoveanu Z., Love-Homan L., Huang W.Q., and Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16 (1998) 1216-1224
37. Klinman D., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFN-g. Proc Natl Acad Sci U S A 93 (1996) 2879-2883
38. Schwartz D.A., Quinn T.J., Thorne P.S., Sayeed S., Yi A.K., and Krieg A.M. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 100 (1997) 68-73
39. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264 (1994) 561-563
40. McCluskie M.J., Weeratna R.D., Krieg A.M., and Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19 (2001) 950-957
41. Mutwiri G.K., Nichani A.K., Babiuk S., and Babiuk L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release 97 (2004) 1-17
42. Freytag L.C., and Clements J.D. Mucosal adjuvants. Vaccine 23 (2005) 1804-1813
43. Holmgren J., Adamsson J., Anju'ere F., Clemens J., Czerkinsky C., and Eriksson K. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97 (2005) 181-188
44. Janeway C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 1 (2002) 197-216
45. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., and Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2 10 (2001) 947-950
46. Kristina D., Mattias M., Maija-Leena E., Lisbeth F., Gunnar V.A., and Caroline F. Characteristics of oligodeoxy-ribonucleotides that induce interferon (IFN)-alpha in the pig and the phenotype of the IFN-alpha producing cells. Vet Immunol Immunopathol 101 1-2 (2004) 87-102
47. Kamstrup S., Daniela V., and Dennis M.K. Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides. Vet Microbiol 78 4 (2001) 353-362
48. Hasslung F.C., Berg M., Allan G.M., Meehan B.M., McNeilly F., and Fossum C. Identification of a sequence from the genome of porcine circovirus type 2 with an inhibitory effect on INF-alpha production by porcine PBMCs. Gen Virol 84 (2003) 2937-2945
49. Van der Stede Y., Verdonck F., Verfaillie T., Goddeeris B.M., and Cox E. Porcine-specific CpG-oligodeoxynucleotide activates B-cells and increases the expression of MHC-II molecules on lymphocytes. Vet Immunol Immunopathol 105 (2005) 115-124
50. Daqing W., Ekambar R.K., Dong Y., Jimmy X.T., and Sudhir A. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine 23 (2005) 2614-2622
51. Amanda K., and Kenneth L.R. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22 (2004) 3098-3104
52. Riffault S., Carrat C., van Reeth K., Pensaert M., and Charley B. Interferon-alpha-producing cells are localized in gut-associated lymphoid tissues in transmissible gastroenteritis virus (TGEV) infected piglets. Vet Res 32 (2001) 71-79
53. Summerfield A., Guzylack-Piriou L., Schaub A., Carrasco C.P., Tache V., Charley B., et al. Porcine peripheral blood dendritic cells and natural interferon-producing cells. Immunology 110 (2003) 440-449
54. Guzylack-Pirou L., Balmelli C., McCullough K.C., and Summerfield A. Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-a, tumor necrosis factor-a and interleukin-12. Immunology 112 (2004) 28-37